In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

被引:197
|
作者
Li, J
Turnidge, J
Milne, R
Nation, RL
Coulthard, K
机构
[1] Univ S Australia, Pharmaceut Res Ctr, Adelaide, SA 5001, Australia
[2] Womens & Childrens Hosp, Dept Infect Dis, Adelaide, SA, Australia
[3] Womens & Childrens Hosp, Dept Pharm, Adelaide, SA, Australia
关键词
D O I
10.1128/AAC.45.3.781-785.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmucoid strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis, Twenty-three clinical strains, including multiresistant strains, and one type strain were selected for MIC determination. Eleven strains were resistant; MICs for these strains were > 128 mg/liter, For the susceptible strains, MICs of colistin ranged from 1 to 4 mg/liter, while the MICs of colistin methanesulfonate were significantly higher and ranged from 4 to 16 mg/liter, The time-kill kinetics were investigated with three strains at drug concentrations ranging from 0.5 to 64 times the MIC. Colistin showed extremely rapid killing, resulting in complete elimination at the highest concentrations within 5 min, while colistin methanesulfonate killed more slowly, requiring a concentration of 16 times the MIC to achieve complete killing within 24 h, Colistin exhibited a significant PAE of 2 to 3 h at 16 times the MIC against the three strains after 15 min of exposure. For colistin methanesulfonate, PAEs were shorter at the concentrations tested. Colistin methanesulfonate had lower overall bactericidal and postantibiotic activities than colistin, even when adjusted for differences in MICs, Our data suggest that doses of colistin methanesulfonate higher than the recommended 2 to 3 mg/kg of body weight every 12 h may be required for the effective treatment of P. aeruginosa infections in cystic fibrosis patients.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [41] In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
    Monogue, Marguerite L.
    Desai, Dhara
    Pybus, Christine A.
    Sanders, James M.
    Clark, Andrew E.
    Greenberg, David E.
    MICROBIOLOGY SPECTRUM, 2023, 11 (06):
  • [42] The efficacy of biosynthesized silver nanoparticles against Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Al-Momani, Hafez
    Almasri, Muna
    Al Balawi, Dua'A.
    Hamed, Saja
    Albiss, Borhan Aldeen
    Aldabaibeh, Nour
    Ibrahim, Lugain
    Albalawi, Hadeel
    Al Haj Mahmoud, Sameer
    Khasawneh, Ashraf I.
    Kilani, Muna
    Aldhafeeri, Muneef
    Bani-Hani, Muayyad
    Wilcox, Matthew
    Pearson, Jeffrey
    Ward, Christopher
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] The efficacy of biosynthesized silver nanoparticles against Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Hafez Al-Momani
    Muna Almasri
    Dua’A. Al Balawi
    Saja Hamed
    Borhan Aldeen Albiss
    Nour Aldabaibeh
    Lugain Ibrahim
    Hadeel Albalawi
    Sameer Al Haj Mahmoud
    Ashraf I. Khasawneh
    Muna Kilani
    Muneef Aldhafeeri
    Muayyad Bani-Hani
    Matthew Wilcox
    Jeffrey Pearson
    Christopher Ward
    Scientific Reports, 13
  • [44] COLISTIN INHALATION-THERAPY IN CYSTIC-FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS-AERUGINOSA LUNG INFECTION
    JENSEN, T
    PEDERSEN, SS
    GARNE, S
    HEILMANN, C
    HOIBY, N
    KOCH, C
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (06) : 831 - 838
  • [45] Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis
    Horianopoulou, M
    Lambropoulos, S
    Papafragas, E
    Falagas, ME
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (05) : 536 - 538
  • [46] Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Pseudomonas aeruginosa Isolated From Cystic Fibrosis Patients
    Molchanova, Natalia
    Wang, Hengzhuang
    Hansen, Paul R.
    Hoiby, Niels
    Nielsen, Hanne M.
    Franzy, Henrik
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [47] Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients
    Vettoretti, Lucie
    Plesiat, Patrick
    Muller, Cedric
    El Garch, Farid
    Phan, Gilles
    Attree, Inna
    Ducruix, Arnaud
    Llanes, Catherine
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (05) : 1987 - 1997
  • [48] Susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients to ciprofloxacin
    Bauernfeind, A
    Jungwirth, R
    Ratjen, F
    DRUGS, 1999, 58 (Suppl 2) : 209 - 210
  • [49] Susceptibility of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients to Ciprofloxacin
    A. Bauernfeind
    R. Jungwirth
    F. Ratjen
    Drugs, 1999, 58 : 209 - 210
  • [50] Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients
    Çagla Bozkurt-Güzel
    Ayse Alev Gerçeker
    The Journal of Antibiotics, 2012, 65 : 83 - 86